PMC:7755033 / 65517-65901 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"902","span":{"begin":67,"end":75},"obj":"Chemical"},{"id":"903","span":{"begin":80,"end":98},"obj":"Chemical"}],"attributes":[{"id":"A903","pred":"tao:has_database_id","subj":"903","obj":"MESH:D006886"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" 6W75) in comparison to the FDA approved standard reference drugs (Losartan and Hydroxychloroquine).\n    AutoDock v4.2.6 AutoDock vina iGEMDOCK v2.1\nS. No. Ligands BE (kcal/mol) K d Interacting amino acids BE(kcal/mol) K d Interacting amino acids TE(kcal/mol) VDW HB EI Interacting amino acids  \n1. Withaferin A –9.33 144.58 nM Asp6906, Asn7095, Ser6907, Thr690"}

{"project":"LitCovid-sentences","denotations":[{"id":"T591","span":{"begin":1,"end":100},"obj":"Sentence"},{"id":"T592","span":{"begin":101,"end":152},"obj":"Sentence"},{"id":"T593","span":{"begin":153,"end":155},"obj":"Sentence"},{"id":"T594","span":{"begin":156,"end":159},"obj":"Sentence"},{"id":"T595","span":{"begin":161,"end":314},"obj":"Sentence"},{"id":"T596","span":{"begin":315,"end":317},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" 6W75) in comparison to the FDA approved standard reference drugs (Losartan and Hydroxychloroquine).\n    AutoDock v4.2.6 AutoDock vina iGEMDOCK v2.1\nS. No. Ligands BE (kcal/mol) K d Interacting amino acids BE(kcal/mol) K d Interacting amino acids TE(kcal/mol) VDW HB EI Interacting amino acids  \n1. Withaferin A –9.33 144.58 nM Asp6906, Asn7095, Ser6907, Thr690"}